- Design
- Physiologically based pharmacokinetic modelling, validated against clinical data
- Population
- Zavegepant nasal spray (acute migraine) interaction scenarios
- Primary outcome
- Predicted change in intranasal zavegepant exposure with interacting drugs
- Effect
- Single-dose rifampin AUC ratio 2.39; cyclosporine 1.58; CYP3A/P-gp effect minimal
Zavegepant, the nasal CGRP-receptor antagonist for acute migraine, is handled by several routes — the liver-uptake transporters OATP1B3 and NTCP, P-glycoprotein and CYP3A4 — which makes its interaction profile non-obvious. Physiologically based modelling, validated against clinical data, sorted out which ones matter for the nasal spray.
For the intranasal route, CYP3A4 and P-glycoprotein inhibitors and inducers had little clinically relevant effect. What mattered was inhibition of the liver-uptake transporters: modelling predicted intranasal zavegepant exposure rose about 2.4-fold with single-dose rifampin and about 1.6-fold with cyclosporine. The practical rule is the reverse of the usual reflex — do not worry about the azole antifungal, but do avoid co-administering an OATP1B3/NTCP inhibitor such as cyclosporine.
The lesson generalises: route of administration changes which interactions count, and a drug with several elimination pathways needs the dominant one identified rather than every pathway flagged.
- Avoid co-administering OATP1B3/NTCP inhibitors (eg, cyclosporine) with zavegepant nasal spray.
- CYP3A4 and P-glycoprotein inhibitors or inducers do not meaningfully change nasal-spray exposure.
- Single-dose rifampin was predicted to raise intranasal zavegepant exposure about 2.4-fold.
- The interaction profile of the nasal spray differs from the oral form — route matters.
Why it matters
It redirects interaction caution to the transporter that matters and away from the CYP3A4 reflex, which does not apply to the nasal route.
Don't overread it
Most of these interaction estimates are PBPK model predictions rather than directly observed, so they guide labelling and caution rather than quantify a measured effect.
The statistics, in plain English
An AUC ratio of about 2.4 means roughly a doubling-plus of drug exposure; these are modelled predictions anchored to some observed data, so the direction is more certain than the exact number.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free